154 related articles for article (PubMed ID: 8874750)
1. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA.
Rajan GP; Seifert B; Prümmer O; Joller-Jemelka HI; Burg G; Dummer R
Arch Dermatol Res; 1996 Aug; 288(9):543-8. PubMed ID: 8874750
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
[TBL] [Abstract][Full Text] [Related]
3. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
5. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
[TBL] [Abstract][Full Text] [Related]
6. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
7. Interferon treatment of cutaneous T-cell lymphoma.
Ross C; Tingsgaard P; Jørgensen H; Vejlsgaard GL
Eur J Haematol; 1993 Aug; 51(2):63-72. PubMed ID: 7690332
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment for cutaneous lymphomas.
Mielke V; Staib G; Sterry W
Recent Results Cancer Res; 1995; 139():403-8. PubMed ID: 7597307
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
10. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.
Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH
J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.
Schiller M; Tsianakas A; Sterry W; Dummer R; Hinke A; Nashan D; Stadler R
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1841-1847. PubMed ID: 28557110
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
14. Follicular mucinosis associated with early stage cutaneous T-cell lymphoma: successful treatment with interferon alpha-2b and acitretin.
Kontochristopoulos GJ; Exadaktylou D; Hatziolou E; Tassidou A; Zakopoulou N
J Dermatolog Treat; 2001 Jun; 12(2):117-21. PubMed ID: 12243671
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy.
Stadler R; Otte HG
Recent Results Cancer Res; 1995; 139():391-401. PubMed ID: 7597306
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi E; Redelotti R; Peserico A; Monfardini S; Salvagno L
Cancer; 2002 Aug; 95(3):569-75. PubMed ID: 12209749
[TBL] [Abstract][Full Text] [Related]
17. [Combination therapy with interferon alfa 2a and PUVA in cutaneous T-cell lymphoma].
Otte HG; Herges A; Stadler R
Hautarzt; 1992 Nov; 43(11):695-9. PubMed ID: 1468931
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
19. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
Ducreux J; Houssiau FA; Vandepapelière P; Jorgensen C; Lazaro E; Spertini F; Colaone F; Roucairol C; Laborie M; Croughs T; Grouard-Vogel G; Lauwerys BR
Rheumatology (Oxford); 2016 Oct; 55(10):1901-5. PubMed ID: 27354683
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.
Kuzel TM; Gilyon K; Springer E; Variakojis D; Kaul K; Bunn PA; Evans L; Roenigk HH; Rosen ST
J Natl Cancer Inst; 1990 Feb; 82(3):203-7. PubMed ID: 2296050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]